J Korean Soc Transplant.  2011 Jun;25(2):113-115.

Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient

• Ahn SH
• Min SK
• Min SI
• Kim SY
• Kim SJ
• Ha J

Abstract

Mycophenolate mofetil (MMF) is being widely used as a maintenance imunosuppressive therapy in renal transplant patients. Myelotoxicity and gastrointestinal symptoms are the well-known adverse effects of this immunosuppressant. However, there areexistonly two reports on oral ulceration associtated with MMF. Although oral ulcerations are not life-threatening, they may seriously affect the quality of life. We report ourthe experience of a case of a 57-year-old female patient with painful oral mucosal ulcerations that improved following MMF discontinuation.

Keyword

Mycophenolate mofetil; Oral ulcer; Kidney transplantation

MeSH Terms

Female
Humans
Kidney Transplantation
Middle Aged
Mycophenolic Acid
Oral Ulcer
Quality of Life
Transplants
Ulcer
Mycophenolic Acid

Figure

• 

  Fig. 1. Development of oral ulcerations during MMF therapy after living-donor kidney transplantation. Photographs show large painful ulcers on the lower lip and the palate.

Reference

References

1). Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995; 345:1321–5.

2). Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996; 36:315–24.

3). Kahan BD. Mycophenolate mofetil. In: Morris PJ, Knechtle SJ. Kidney transplantation. Philadelphia, PA: Saunders elsevier;2008. p. 277–92.

4). Garrigue V, Canet S, Dereure O, Panabieres O, Augias D, Chong G, et al. Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? Transplantation. 2001; 72:968–9.

5). Apostolou T, Tsagalis G, Koutroubas G, Hadjiconstantinou V, Drakopoulos S. Mycophenolate mofetil and oral ulcerations. Transplantation. 2004; 77:1911–2.

6). Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against longterm renal allograft function deterioration. Transplantation. 2003; 75:1341–6.

7). Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi MA, Weimert NA, et al. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation. 2009; 87:408–14.

8). Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation. 2000; 70:1244–7.

9). MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001; 71:271–80.

10). Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000; 69:1252–60.

11). Fricain JC, Cellerie K, Sibaud V, Catros S, Taieb A, Merville P. [Oral ulcers in kidney allograft recipients treated with sirolimus]. Ann Dermatol Venereol. 2008; 135:737–41.

12). Mawardi H, Pavlakis M, Mandelbrot D, Woo SB. Sirolimus oral ulcer with Cedecea davisae superinfection. Transpl Infect Dis. 2010; 12:446–50.